KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

J Clin Oncol · 2026-Jun-10 · PMID 41369677

Panel Kaplan-Meier_estimate_of_PFS_in_the_ITT_analysis_population质量警告待 EXE 对齐验证

PFS

FIG A1. Kaplan-Meier estimate of PFS in the ITT analysis population assessed by blinded independent central review. HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.79
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T17:04:00+00:00